Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study

MLA

Biagio Di Iorio, et al. “Erratum to: Sevelamer Is Cost Effective versus Calcium Carbonate for the First-Line Treatment of Hyperphosphatemia in New Patients to Hemodialysis: A Patient-Level Economic Evaluation of the INDEPENDENT-HD Study.” Journal of Nephrology, vol. 27, Aug. 2014, p. 717. EBSCOhost, https://doi.org/10.1007/s40620-014-0128-2.

APA

Biagio Di Iorio, Domenico Russo, Donald A. Molony, Matteo Ruggeri, Antonio Bellasi, Filippo Cipriani, & Cynthia S. Bell. (2014). Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. Journal of Nephrology, 27, 717. https://doi.org/10.1007/s40620-014-0128-2

Chicago

Biagio Di Iorio, Domenico Russo, Donald A. Molony, Matteo Ruggeri, Antonio Bellasi, Filippo Cipriani, and Cynthia S. Bell. 2014. “Erratum to: Sevelamer Is Cost Effective versus Calcium Carbonate for the First-Line Treatment of Hyperphosphatemia in New Patients to Hemodialysis: A Patient-Level Economic Evaluation of the INDEPENDENT-HD Study.” Journal of Nephrology 27 (August): 717. doi:10.1007/s40620-014-0128-2.